Business Insider

EyeGate Files Supplement to Investigational Device Exemption to Commence Study in Punctate Epitheliopathy using the EyeGate Ocular Bandage GelContinued Expansion of the EyeGate ...

WALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary ...
GEN

EyeGate Licenses Uveitis Treatment, Delivery System to Valeant

EyeGate Pharmaceuticals said today it has licensed its clinical-phase sole product candidate for uveitis, final-negotiation rights to license the treatment for other indications, and the drug’s ...
Business Insider

EyeGate Pharma Submits Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel

WALTHAM, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary ...
FiercePharma

Valeant to commercialize and manufacture EyeGate's eye drug delivery device

Valeant Pharmaceuticals ($VRX) will commercialize and manufacture a delivery system and reformulated, topically active corticosteroid to treat uveitis developed by ...
Nasdaq

EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation

WALTHAM, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and ...